Genes explain GLP‑1 response

# Genes explain why GLP-1 drugs work differently from person to person Two people can take the same weight-loss drug, at the same dose, and get very different results. One may lose a large amount of weight with manageable nausea, while another may lose much less and stop early because of stomach problems. A new genetics study offers one reason why: some of that variation appears to be written into our DNA. (Nature: ) The drugs in question are called glucagon-like peptide 1 receptor agonists, often shortened to GLP-1 drugs. Medicines in this group include semaglutide and tirzepatide, which are sold under brand names such as Wegovy, Ozempic, Zepbound and Mounjaro for obesity or type 2 diabetes, depending on the product and indication. (Nature: ) These medicines work by mimicking hormone signals involved in appetite and digestion. In simple terms, they help people feel full sooner, stay full longer, and in many cases eat less over time. (Scientific American: ) But the response is famously uneven. Some patients lose more than 15% of their body weight, while others lose much less, and gastrointestinal side effects such as nausea, vomiting, diarrhea and constipation are common enough to shape whether people stay on treatment. (Nature: ) (Frontiers in Pharmacology: ) The new study, published in *Nature* on April 8, 2026, analyzed data from nearly 28,000 people. The researchers used genetic and self-reported treatment data from participants in the 23andMe research database to look for DNA variants linked to weight-loss response and side effects from GLP-1 medicines. (Nature paper: ) (23andMe Research Institute: ) What they found was not a single “weight-loss gene,” but a set of genetic clues. Variants in or near genes including GLP1R and GIPR were associated with differences in how much weight people lost on these drugs, and other variants were linked to a higher chance of gastrointestinal side effects. (Nature paper: ) (Springer Nature Communities: ) Those gene names matter because they sit close to the biology the drugs are already targeting. GLP1R encodes the receptor that GLP-1 drugs act on, and GIPR encodes the receptor for glucose-dependent insulinotropic polypeptide, another hormone pathway involved in metabolism and appetite regulation. Tirzepatide is especially relevant here because it acts on both the GLP-1 and GIP pathways. (Nature paper: ) (Nature News: ) That makes the result more than a fishing expedition. If people with certain variants respond differently in the very pathways these drugs use, it strengthens the idea that biology, not just willpower, adherence, or chance, helps determine who benefits most and who struggles with side effects. This is an inference from the study’s findings, not a direct clinical rule. (Nature paper: ) (Scientific American: ) The side-effect finding may be especially important in practice. Nausea and other gastrointestinal symptoms are among the main reasons patients reduce their dose or stop treatment, so a genetic signal tied to side-effect risk could eventually help doctors decide who needs slower dose escalation, closer follow-up, or a different drug choice. (Nature News: ) (23andMe Research Institute: ) The study does not mean a DNA test can already tell someone exactly how much weight they will lose. Researchers and outside experts both note that genetics explains only part of the story, and factors such as dose, duration of treatment, diet, exercise, other health conditions, and whether a person can stay on the drug still matter a great deal. (Scientific American: ) (Nature News: ) There are also limits in the data. Much of the treatment information was self-reported, and self-reported outcomes can be noisier than measurements collected in a controlled clinical trial. That does not erase the findings, but it means the results will need replication and validation in additional groups before they can guide routine prescribing. (Nature paper: ) (Nature News: ) Even so, the study points toward a future in which obesity treatment looks more like other areas of precision medicine. Instead of asking only whether a GLP-1 drug works on average, doctors may eventually ask which patient is most likely to respond to which drug, at what dose, and with what side-effect risk. (Nature paper: ) (23andMe Research Institute: ) That is a big shift because GLP-1 medicines have already changed obesity care before the science of matching them to patients has caught up. This new paper does not finish that job, but it gives researchers a map: the genes most tied to response seem to be the same genes sitting inside the drug pathways themselves. (Nature News: ) (Springer Nature Communities: ) For patients, the immediate takeaway is modest but useful. If a GLP-1 drug works extremely well for one person and poorly for another, that difference may not be random, and it may not be a personal failure either. Part of the answer may be genetic. (Nature News: )